Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.67 |
| ▸ | PPARA | Q07869 | 2/20 | 0.67 |
| ▸ | SGK1 | O00141 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13774946 | 0.93 | PPARD (0.56) | PPARDPPARASGK1PTGS2MAPT | |
| SCHEMBL4194366 | 0.92 | PPARD (0.77) | PPARDPPARAMAPTRAB9AL3MBTL1 | |
| SCHEMBL4190207 | 0.91 | PPARD (0.55) | PPARDPPARASGK1PTGS2MAPT | |
| SCHEMBL4180044 | 0.90 | PPARD (0.73) | PPARDPPARAMAPTRAB9AL3MBTL1 | |
| SCHEMBL4194591 | 0.89 | PPARD (0.72) | PPARDPPARAMAPTRAB9AL3MBTL1 | |
| SCHEMBL4188963 | 0.88 | PPARD (0.73) | PPARDPPARAMAPTRAB9AL3MBTL1 | |
| SCHEMBL4186781 | 0.87 | PPARD (0.69) | PPARDPPARAMAPTRAB9AL3MBTL1 | |
| SCHEMBL4182924 | 0.86 | PPARD (0.74) | PPARDPPARA | |
| SCHEMBL4183182 | 0.86 | PPARD (0.67) | PPARDPPARAL3MBTL1 | |
| SCHEMBL4187381 | 0.86 | PPARD (0.67) | PPARDPPARAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | claimed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| EP-1945620-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056366-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885SGK1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.